Molecular Glue Degraders Development Platform
Our company has an experienced team of experts who can provide you with complete rare disease therapy and drug development solutions. At the same time, we have rich experience in protein degradation. Our molecular glue degrader development platform can provide you with professional and comprehensive services for rare disease research.
Introduction to Molecular Glue Degraders
Molecular glue degraders are small molecules that allow precise temporal control of various biological processes, such as signal transduction, translation, chromatin regulation, protein folding, localization, and degradation. As chemical inducers of molecular interactions, molecular glue degraders promote the dimerization or colocalization of two proteins by forming ternary complexes, resulting in a variety of biological and pharmacological functions.
Molecular glue degraders can combine with E3 ubiquitin ligase and contact the target protein with its help, resulting in polyubiquitination and proteasome degradation of the target protein, thus destabilizing it. Molecular glue mediates proximity-induced protein degradation and has inherent advantages over PROTACs, including unprecedented mechanisms, unique biological activities, and good physical and chemical properties.
Fig.1 The schematic diagram of molecular glue-mediated protein degradation. (Dong G., et al., 2021)
Molecular Glue Degraders for Rare Diseases
Targeting protein degradation is a promising area of drug discovery and the development of innovative therapies for rare diseases. Using small-molecule degraders to redirect cellular machinery to destroy proteins opens up new possibilities for the therapeutics of rare diseases. Currently, some molecular glue targets have been used in the research of rare diseases:
| Molecular Glue Targets | Indications |
|---|---|
| GSPT1 | Acute Myeloblastic Leukemia |
| CRBN | Acute Myeloblastic Leukemia / Multiple Myeloma / Lymphoma |
| IKZF2 | Colorectal Cancer |
| IKZF1/3 | Multiple Myeloma |
| GSPT1 | Multiple Myeloma |
Our Services
Our company continues to develop new technologies for molecular glue development. To better complete the development of molecular glues in rare disease research, we provide preclinical research services and combine our one-stop molecular glue degrader development platform to ensure that we can quickly respond to the changing needs of your research projects.
- Molecular Glue Screening and Synthesis
Due to the lack of general principles and systematic methods, preparing large and diverse molecular gel libraries is not a simple task. Our one-stop molecular glue development platform can provide you with screening services for natural molecular glues, synthesis services for non-natural molecular glues, and modification services for molecular glues. - Validation Studies for Molecular Glue
To better complete the development of molecular glues, we provide a complete suite of validation studies to establish binding, ternary complex formation, and cellular degradation. Our molecular glue degrader development platform can provide efficient methods to accelerate your research into rare diseases.
Molecular Glues Degraders Development Technologies
High-Throughput Screening
Computer-Aided Drug Design
Mass SpectrometryOur Advantages
- Reducing costs and time by enabling more efficient processes through service expertise
- One-stop platform with an experienced technical team
- Superior data quality and fast turnaround
- Timely project reporting and after-sales service
Project Workflow
With many years of experience and a proven track record of quality, innovation, and customer support, our company provides comprehensive services for leading and emerging biopharmaceutical companies and scientific research institutions to develop molecular glues for rare diseases. If you need our service and technical support in the molecular glues development program, please contact us and send your detailed request.
Reference
- Dong G., et al. "Molecular glues for targeted protein degradation: from serendipity to rational discovery." Journal of medicinal chemistry 64.15 (2021): 10606-10620
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
